S_..ary The immunohistochemical expression of tenascin was examined in the normal adult mucosa of the stomach, primary tumours and lymph node metastases of gastric cancer patients. In normal gastric tissue tenascin was expressed in the muscularis mucosae, musclaris propnra and vessel walls, however it was not expressed in either the (Erickson and Bourdon, 1989) , and was initially detected as a marker for tendon and muscle morphogenesis in chicks (Chiquet and Fambrough, 1984; ChiquetEhrismann et al., 1986). Recent studies have demonstrated the appearance of tenascin during fetal development in organs such as the gut (Aufderheide and Ekblon, 1988) and kidney (Aufderheide et al., 1987), as well as in the stromal tissues of benign and malignant tumours (Mackie et al., 1987; Erickson and Lightner, 1988; Erickson and Bourdon, 1989; Vollmer et al., 1990; Natali et al., 1990 Natali et al., , 1991 Sakakura et al., 1991; Shoji et al., 1992; Sakai et al., 1993; Soini et al., 1993a,b; Ramkissoon et al., 1994 (Lauren, 1965; Nakamura et al., 1968; Ming, 1977; Sugano et al., 1982 
Tenascin is a glycoprotein component of the extracellular matrix with a six-armed macromolecular structure of a disulphide-bonded oligomer (Chiquet-Ehrismann et al., 1986) , consisting of three isoforms of the molecules with a molecular weight of 190, 200, 230 kDa (Chiquet-Ehrismann et al., 1991) . Tenascin is synthesised by fibroblasts and glial cells (Erickson and Bourdon, 1989) , and was initially detected as a marker for tendon and muscle morphogenesis in chicks (Chiquet and Fambrough, 1984; ChiquetEhrismann et al., 1986) . Recent studies have demonstrated the appearance of tenascin during fetal development in organs such as the gut (Aufderheide and Ekblon, 1988) and kidney (Aufderheide et al., 1987) , as well as in the stromal tissues of benign and malignant tumours (Mackie et al., 1987; Erickson and Lightner, 1988; Erickson and Bourdon, 1989; Vollmer et al., 1990; Natali et al., 1990 Natali et al., , 1991 Sakakura et al., 1991; Shoji et al., 1992; Sakai et al., 1993; Soini et al., 1993a,b; Ramkissoon et al., 1994 (Soini et al., 1993a) . malignant bone marrow disease (Soini et al.. 1993b) and malignant melanoma (Natali et al., 1990) . Tenascin has been isolated from cultured fibroblasts and cultured medium (Oike et al.. 1990) . and tenascin synthesis in fibroblasts is also induced by tumour growth factor beta (TGF-P) Erickson and Bourdon, 1989; ChiquetEhrismann, 1990 (Sakai et al., 1993) and, while the expression of tenascin in gastric cancer also shows the same tendency, the difference is not statistically significant. The existence of positive expression of tenascin in normal gland tissues remains controversial. In the mammary glands. tenascin has been reported to be prominent in malignant disease, but it is rare in benign mammary lesions or normal tissue (Mackie et al., 1987) . In contrast, Howeedy et al. (1990) concluded that tenascin is not a transient extracellular matrix component restricted to development and transformation but may be viewed as a consistent, albeit variably distributed, component of the normal and pathological periepithelial stromal regions. In colonic tissue, tenascin has been described in the basement membrane of the mucosal epithelium, muscularis mucosae and the muscularis propria of normal adult colon (Oike et al., 1990; Riedl et al., 1992) . And Sakai et al. (1993) reported the distinct localisation of tenascin in the stroma of tubular adenomas as well as in the superficial layer of well-differentiated adenocarcinomas; they also reported an absence of tenascin in normal mucosa. These discrepancies may be explained by the use of different kinds of monoclonal antibodies and by differing sensitivity of the antibody depending on tissue preparation. e.g. frozen sections of paraffin-embedded sections (Sakai et al., 1993) . In contrast to the controversy surrounding the expression of tenascin in normal tissue, the expression of tenascin appears more intense in the stromal tissue of human neoplasms than in normal tissue. With regard to the stomach, only a few studies have been carried out (Natali et al., 1991; Ramkissoon et al., 1994) . In the present study tenascin was expressed in the muscularis mucosae, the muscularis propria and the vessel walls of the stomach, but not in the mucosa or submucosal connective tissue, which is consistent with the findings of Natali et al. (1991) or Ramkissoon et al. (1994) .
In summary, tenascin appears during the process of either malignant transformation or tumour progression in gastric cancer, while the positive expression of tenascin in gastric cancer is not necessarily considered to indicate clinically malignant potential such as lymph node metastasis or prognosis.
